Pharmaceutical Investing Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meetin
Cartier Resources Announces Subscription Agreement for Flow-Through Units Under Its Previously Announced Brokered Offering and Adjustments Further to Tax Measures Unveiled by the Quebec Minister of Finance
